Michael Davenport

Mr. Michael Davenport

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2006 in Journal of Neurotrauma
Verified
Journal Article
Closed access
VAVictor L. Arvanian
Victor L. Arvanian
HMHoneyleen Manuzon
Honeyleen Manuzon
MDMichael Davenport
Michael Davenport
GBGeorgia Bushell
Georgia Bushell
LMLorne M. Mendell
Lorne M. Mendell
JRJohn K. Robinson
John K. Robinson
We explored functional recovery in two spinal cord injury models following a novel combination treatment (NT-3 + LSD). One group of rats received a staggered double hemisection (DH) at postnatal day 2 (P2) of the left hemicord at T11 and the right hemicord at T12. Another group received complete transection (CT) at T11 on P2. A third group was sham operated. Each of these groups was also treated with the drug combination. Drugs were administered intrathecally above the lesion during surgery, and again s.c. at P4, P6, P8, and P10. Intracellular recording in an in vitro spinal cord preparation at P10–P12 in DH rats revealed weak polysynaptic connections to lumbar motoneurons through the injury region, but only in those receiving NT-3 + LSD; NT-3 or LSD alone had no effect. In behavioral experiments, the frequency of rearing in an open field and hindlimb kicks during swimming was assessed every 3–4 days from P9 to P58. Both CT and DH injury severely impaired rearing and hindlimb kicking during swimming. DH rats treated with NT-3 + LSD showed significantly more kicks during swimming than untreated DH or CT rats and treated CT rats beginning as early as P9 and lasting through the duration of testing. Rearing behavior was also improved by treatment but beginning only in the 3rd postnatal week, the time at which it normally develops. Rearing frequency reached sham control levels by P40. Our results suggest this combination treatment may be a promising new strategy for facilitating recovery from moderate spinal cord injury.

30 January 2026 in Journal of the American Heart Association
Verified
Journal Article
Open access
SASonia T Anand
Sonia T Anand
CHCynthia Hau
Cynthia Hau
MDMichael Davenport
Michael Davenport
AIAreef Ishani
Areef Ishani
WCWilliam C. Cushman
William C. Cushman
SLSarah M. Leatherman
Sarah M. Leatherman
Background: The DCP (Diuretic Comparison Project), a pragmatic trial, evaluated whether chlorthalidone compared with hydrochlorothiazide would reduce the risk of nonfatal cardiovascular disease or noncancer‐related death. The intent‐to‐treat analysis found no difference in such comparison (hazard ratio, 1.04 [95% CI, 0.94–1.16]). The objective of the current study is to estimate the per‐protocol effect of chlorthalidone (12.5/25 mg daily) compared with hydrochlorothiazide (25/50 mg daily) in preventing major adverse cardiovascular events among older patients with hypertension. Methods: The effect of adhering to treatment strategies was assessed by censoring at first instance of nonadherence, defined as a gap (>90‐day gap in drug coverage), switch (switching between study medications), and discontinuation (stop taking chlorthalidone/hydrochlorothiazide altogether for >90 days before the end of the study). The primary outcome was a composite of nonfatal myocardial infarction, stroke, heart failure resulting in hospitalization, urgent coronary revascularization for unstable angina, and noncancer‐related death. Using inverse probability weighting, we evaluated the per‐protocol effect of chlorthalidone and hydrochlorothiazide using DCP trial data. Results: Nonadherence was found in 5476 (40%) participants; among 8047 (60%) adherents, 3905 (49%) were randomized to chlorthalidone and 4142 (51%) to hydrochlorothiazide. After censoring time when participants deviated from the assigned treatments, the estimated 5‐year risk ratio of the composite primary outcome of nonfatal cardiovascular disease and noncancer‐related death was 1.36 (95% CI, 0.96–2.12) in chlorthalidone compared with hydrochlorothiazide. Conclusions: The per‐protocol analysis indicated a lower risk with hydrochlorothiazide compared with chlorthalidone in preventing nonfatal cardiovascular disease and noncancer‐related death; however, this difference was not statistically significant using dispensation data to identify adherence. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02185417.

1 May 2025 in Journal of Psychopathology and Clinical Science
Verified
Journal Article
Closed access
NLNicholas Livingston
Nicholas Livingston
AMAmar D. Mandavia
Amar D. Mandavia
ABAnne N. Banducci
Anne N. Banducci
RHRebecca Sistad Hall
Rebecca Sistad Hall
LLLauren B. Loeffel
Lauren B. Loeffel
FMFrank Meng
Frank Meng
Novel and automated means of opioid use and relapse risk detection are needed. Unstructured electronic medical record data, including written progress notes, can be mined for clinically relevant information, including the presence of substance use and relapse-critical markers of risk and recovery from opioid use disorder (OUD). In this study, we used natural language processing (NLP) to automate the extraction of opioid relapses, and the timing of these occurrences, from veteran patients' electronic medical record. We then demonstrated the utility of our NLP tool via analysis of pre-/post-COVID-19 opioid relapse trends among veterans with OUD. For this demonstration, we analyzed data from 107,606 veterans OUD enrolled in Veterans Health Administration, comparing a pandemic-exposed cohort (n = 53,803; January 2019-March 2021) to a matched prepandemic cohort (n = 53,803; October 2017-December 2019). The recall of our NLP tool was 75% and our precision was 94%, demonstrating moderate sensitivity and excellent specificity. Using the NLP tool, we found that the odds of opioid relapse postpandemic onset were proportionally higher compared to prepandemic trends, despite patients having fewer mental health encounters from which to derive instances of relapse postpandemic onset. In this research application of the tool, and as hypothesized, we found that opioid relapse risk was elevated postpandemic. The application of NLP methods to identify and monitor relapse risk holds promise for future surveillance, risk prevention, and clinical outcome research. (PsycInfo Database Record (c) 2025 APA, all rights reserved).

Jimmy Thomas EfirdJimmy Thomas Efird
Jimmy Thomas Efird
GDGenevieve N. Dupuis
Genevieve N. Dupuis
YCYuk Ming Choi
Yuk Ming Choi
CHCynthia Hau
Cynthia Hau
SASonia T Anand
Sonia T Anand
HWHongsheng Wu
Hongsheng Wu
Results of a clinical trial may misrepresent the target population. Inappropriate inclusion/exclusion criteria, selective recruitment, and differential participation may restrict the number of patients who consent to join the study. Frequently, they differ from the real-world population in terms of key outcome-related characteristics. Such biased selection may make the therapeutic agent seem more or less effective within a certain stratum. While block randomization and an intent-to-treat design can help to minimize confounding within the trial sample, differences may still exist with respect to the distribution of these variables in the population. To mitigate misleading conclusions, the current manuscript illustrates how to ‘population-adjust’ survival estimates in a clinical trial using the Beckett–Bayes expansion method. In contrast to other population adjustment methods, this novel approach involves substituting the probability of belonging to a specific sample stratum with the corresponding population data (i.e., population borrowing). As a regression-free technique, the method is not susceptible to model misspecification. A large clinical trial focusing on cardiovascular-related deaths in patients with hypertension is used as an example to illustrate the method. The proposed framework is promising and easy to implement when reliable population-level information is available.

24 March 2017 in European Urology Supplements
Verified
Journal Article
Closed access
SSSimpa Samuel Salami
Simpa Samuel Salami
DHD. Hovelson
D. Hovelson
AUA. Udager
A. Udager
MLM. Lee
M. Lee
NCN. Curci
N. Curci
GPG. Palapattu
G. Palapattu

1 January 2026 in Open Medicine
Verified
Journal Article
Open access
SASonia T Anand
Sonia T Anand
CHCynthia Hau
Cynthia Hau
MDMichael Davenport
Michael Davenport
AIAreef Ishani
Areef Ishani
WCWilliam C. Cushman
William C. Cushman
SLSarah M. Leatherman
Sarah M. Leatherman
Objectives: Pragmatic clinical trials leveraging real-world data, such as the Diuretic Comparison Project (DCP), present unique challenges in measuring treatment adherence compared to traditional randomized controlled trials. In DCP, medications were managed through routine VA care and monitored via pharmacy claims, requiring tailored methods to assess adherence beyond standard measures like medication possession ratio (MPR). To develop a data-driven approach to define protocol treatment adherence for pragmatic comparative effectiveness trials. Methods: Structured EHR pharmacy dispense records guided categorization of treatment changes for two diuretics – chlorthalidone (CTD) and hydrochlorothiazide (HCTZ). We examined fill intervals, total drug supply, filling patterns among others to identify prescribing characteristics informing medication adherence definitions and time censoring for per-protocol analysis. Results: Nonadherence was defined as having a gap (>90-days pause in assigned treatment), switch (receiving the other study medication), or discontinuation (without CTD/HCTZ for >90-days). 5,476 patients met nonadherence criteria – 2,851 (52 %) in CTD and 2,625 (48 %) in HCTZ. Switching occurred earlier in CTD patients, gaps were more common in HCTZ, but discontinuation was similar between groups. Conclusions: Defining adherence requires complex decision-making hybrid framework entailing both clinical and statistical expertise. Pragmatic studies should allow flexibility to generate data-driven, clinically-sensitive measures that appropriately describe trial compliance.